
Trigemina, a company focused on creating non-narcotic pain
relief drugs, is enrolling patients in a Phase II
clinical
trial of inhaled oxytocin to treat chronic migraine. Trigemina's oxytocin
product, known as T1-001 (no doubt to be renamed to something lyrical if it
comes to market), has already shown promising results in preliminary studies,
the company says.
This
use makes perfect sense: Oxytocin is a general analgesic (pain reducer), and it
also contributes to relaxation and healing.